Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. develops induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. Its platform uses an iPSC cell foundry and Allo-Evasion™ immune-evasion engineering to create allogeneic beta islet, T cell and natural killer cell programs, including CNTY-813 for type 1 diabetes and CD19-targeted CAR-iT work such as CNTY-308.
Recurring company updates address preclinical data presentations, regulatory-pathway disclosures, financial results, investor presentations, board and committee changes, and collaboration economics tied to the company’s collaboration, option and license agreement with Bristol-Myers Squibb.
Century Therapeutics (NASDAQ: IPSC) reported its second-quarter financial results for 2021, highlighting significant developments and financial positions. The company raised approximately $221 million in a recent IPO, with cash, cash equivalents, and marketable securities totaling $440 million as of June 30, 2021. R&D expenses increased to $18.9 million, while G&A expenses rose to $4.1 million. The net loss for the quarter was $23.3 million, compared to $15.3 million in Q2 2020. The lead program, CNTY-101, is on track for IND filing in mid-2022.
Century Therapeutics (NASDAQ: IPSC) has successfully closed its initial public offering, selling 12,132,500 shares at $20.00 per share, raising approximately $242.7 million before expenses. This includes the underwriters' option for additional shares. The offering was facilitated by J.P. Morgan, BofA Securities, SVB Leerink, and Piper Sandler. The funds will support the development of iPSC-derived cell therapies aimed at treating cancer. A registration statement was filed and effective on June 17, 2021.
Century Therapeutics has priced its initial public offering (IPO) at $20.00 per share, offering 10,550,000 shares of common stock, expected to generate gross proceeds of $211 million. The stock will begin trading on Nasdaq under the symbol 'IPSC' on June 18, 2021, with the offering closing on June 22, 2021. J.P. Morgan, BofA Securities, SVB Leerink, and Piper Sandler are managing the deal. Century focuses on developing iPSC-derived cell therapies for cancer treatment, aiming to enhance patient access and care efficiency.